Trading Report: The Creative Planning invests in 22,006 by buying Sanofi (SNY) shares

The Creative Planning invests in 22,006 by buying Sanofi (SNY) shares

Creative Planning increased its position in Sanofi (NYSE:SNY) by 97.1% during the third quarter, according to its most recent disclosure with the SEC. The firm owned 44,672 shares of the company’s stock after buying an additional 22,006 shares during the period. Creative Planning’s holdings in Sanofi were worth $1,706,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently bought and sold shares of SNY. Rehmann Capital Advisory Group boosted its stake in Sanofi by 0.5% in the second quarter. Rehmann Capital Advisory Group now owns 5,571 shares of the company’s stock worth $233,000 after buying an additional 26 shares during the last quarter. Courier Capital Corp boosted its stake in Sanofi by 0.3% in the second quarter. Courier Capital Corp now owns 42,635 shares of the company’s stock worth $1,784,000 after buying an additional 109 shares during the last quarter. Everett Harris & Co. CA boosted its stake in Sanofi by 1.0% in the second quarter. Everett Harris & Co. CA now owns 10,539 shares of the company’s stock worth $441,000 after buying an additional 109 shares during the last quarter. First Manhattan Co. boosted its stake in Sanofi by 0.6% in the second quarter. First Manhattan Co. now owns 19,281 shares of the company’s stock worth $806,000 after buying an additional 113 shares during the last quarter. Finally, JFS Wealth Advisors LLC boosted its stake in Sanofi by 3.5% in the second quarter. JFS Wealth Advisors LLC now owns 3,961 shares of the company’s stock worth $166,000 after buying an additional 134 shares during the last quarter. 9.58% of the stock is owned by institutional investors.

Shares of Sanofi (NYSE:SNY) traded up 1.01% during mid-day trading on Friday, hitting $39.84. The stock had a trading volume of 710,745 shares. The firm’s 50 day moving average price is $39.19 and its 200-day moving average price is $39.82. The company has a market cap of $102.55 billion, a PE ratio of 23.10 and a beta of 0.97. Sanofi has a one year low of $36.81 and a one year high of $44.76.

A number of equities analysts have recently issued reports on the company. Piper Jaffray Cos. assumed coverage on Sanofi in a research note on Friday, September 23rd. They set a “neutral” rating for the company. Berenberg Bank raised Sanofi from a “hold” rating to a “buy” rating in a research note on Thursday, September 8th. Leerink Swann reissued a “buy” rating on shares of Sanofi in a research note on Monday, September 26th. Jefferies Group reissued a “hold” rating on shares of Sanofi in a research note on Wednesday, September 14th. Finally, Goldman Sachs Group Inc. assumed coverage on Sanofi in a research note on Monday, November 7th. They set a “neutral” rating for the company. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and five have issued a buy rating to the stock. The company currently has an average rating of “Hold” and an average target price of $60.50.

Sanofi Company Profile

Sanofi, formerly Sanofi-Aventis, is a healthcare company engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company operates through three segments: Pharmaceuticals, Human Vaccines (Vaccines) and Animal Health. The Pharmaceuticals segment consists of research, development, production and marketing of medicines, including those originating from Genzyme Corporation.

Related posts

Leave a Comment